205448-28-8

Basic information

• Product Name: 5-{[(3-(benzyloxy)-4-methoxyphenyl)amino]methylene}-2,2-dimethyl-1,3-dioxane-4,6- dione
• Synonyms: 5-{[(3-(benzyloxy)-4-methoxyphenyl)amino]methylene}-2,2-dimethyl-1,3-dioxane-4,6- dione
• CAS NO: 205448-28-8
• Molecular Weight: 383.401
• Mol File: 205448-28-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-{[(3-(benzyloxy)-4-methoxyphenyl)amino]methylene}-2,2-dimethyl-1,3-dioxane-4,6- dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-{[(3-(benzyloxy)-4-methoxyphenyl)amino]methylene}-2,2-dimethyl-1,3-dioxane-4,6- dione(205448-28-8)
• EPA Substance Registry System: 5-{[(3-(benzyloxy)-4-methoxyphenyl)amino]methylene}-2,2-dimethyl-1,3-dioxane-4,6- dione(205448-28-8)

Safety Data

• Hazardous Substances Data: 205448-28-8(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 636-93-1 5-nitroguaiacol 
• 2033-24-1 cycl-isopropylidene malonate 
• 61324-40-1 3-benzyloxy-4-methoxybenzeneamine 
• 122-51-0 orthoformic acid triethyl ester 
• 75167-86-1 2-(benzyloxy)-1-methoxy-4-nitrobenzene 
• 40925-70-0 2-amino-5-methoxyphenol 
• 205448-27-7 5-{[(3-hydroxy-4-methoxyphenyl)amino]methylene}-2,2-dimethyl-1,3-dioxane-4,6-dione 

Downstream Products

• 205448-31-3 4-chloro-6-methoxy-7-hydroxyquinoline 
• 347161-74-4 4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluoroaniline 
• 1394166-10-9 4-(2-fluoro-4-nitrophenyloxy)-6-methoxy-7-[3-(1-pyrrolidyl)propyloxy]quinoline 
• 960299-44-9 4-(3-((4-(2-fluoro-4-nitrophenoxy)-6-methoxyquinolin-7-yl)oxy)propyl)morpholine 
• 1416320-80-3 N'-(3-fluoro-4-{[6-methoxy-7-({1-[(methylamino)-2-oxoethyl]piperidin-4-yl}oxy)quinolin-4-yl]oxy}phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 479690-08-9 1-(2-fluoro-4-nitrophenyl)-6-hydroxy-7-methoxy-quinoline 
• 479690-03-4 7-benzyloxy-4-(2-fluoro-4-nitro-phenoxy)-6-methyloxyquinoline 
• 286371-49-1 7-(benzyloxy)-4-chloro-6-methoxyquinoline 

Relevant articles and documents

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.

Quinoline derivatives (by machine translation)

A compound represented by general formula (I) (I) has a strong Axl inhibiting activity by introducing a distinctive bicyclic structure in which a saturated carbocyclic ring is fused to a pyridone ring, and thus may be used as a therapeutic agent for Axl related diseases such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, cancer such as glioma, kidney disease, immune system disease, and circulatory system disease.